During the past decade, Allergy and Asthma Clinical Research Inc conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 13 clinical trials were completed, i.e. on average, 76.5% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 6 clinical trials were completed. i.e. 85.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Allergy and Asthma Clinical Research Inc" #1 sponsor was "Shire" with 13 trials, followed by "Hoffmann-La Roche" with 4 trials sponsored, "Meda Pharmaceuticals" with 4 trials sponsored, "CSL Behring" with 3 trials sponsored and "Optinose US Inc." with 3 trials sponsored. Other sponsors include 7 different institutions and companies that sponsored additional 17 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Allergy and Asthma Clinical Research Inc" #1 collaborator was "Takeda Development Center Americas, Inc." with 2 trials as a collaborator, "Dyax Corp." with 1 trials as a collaborator, "Genentech, Inc." with 1 trials as a collaborator, "Sanofi" with 1 trials as a collaborator and "Syneos Health" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Allergy and Asthma Clinical Research Inc" are "Hereditary Angioedema" (10 trials), "Asthma" (7 trials), "Hereditary Angioedema (HAE)" (5 trials), "Angioedema" (2 trials) and "Chronic Rhinosinusitis" (2 trials). Many other conditions were trialed in "Allergy and Asthma Clinical Research Inc" in a lesser frequency.

Most popular intervention types in "Allergy and Asthma Clinical Research Inc" are "Drug" (31 trials), "Biological" (11 trials) and "Other" (3 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (16 trials), "C1 esterase inhibitor [human] (C1INH-nf)" (5 trials), "Omalizumab" (3 trials), "0.15% azelastine hydrochloride" (2 trials) and "CSL312" (2 trials). Other intervention names were less common.

The vast majority of trials in "Allergy and Asthma Clinical Research Inc" are 38 trials for "All" genders.

Currently, there are NaN active trials in "Allergy and Asthma Clinical Research Inc". undefined are not yet recruiting, 2 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 33 completed trials in Allergy and Asthma Clinical Research Inc, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Allergy and Asthma Clinical Research Inc, 3 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 24 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".